Atilotrelvir

Atilotrelvir (development code GST-HG171) is a drug for the treatment of COVID-19. It has broad-spectrum anti-SARS-CoV-2 activity against different variants (including WT, β, δ, and omicron). In combination with ritonavir, it was approved for use in China in 2023.
Wikipedia contributors, "Atilotrelvir", Wikipedia, revision 1371307141, retrieved 20 November 2026, source, CC BY-SA 4.0.